Recent Updates
Recently added Catalysts
COYA Positive Sentiment

Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference

Tuesday, October 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Coya Therapeutics, a clinical-stage biotechnology firm, announced its participation in Chardan's 10th Annual Healthcare Conference on October 20 in New York. The panel discussion will focus on targeting neurodegenerative and neuromuscular diseases, including ALS, DMD, and Alzheimer's. This event showcases Coya's commitment to addressing critical health challenges.

Market Sentiment Analysis

POSITIVE FACTORS

  • Coya Therapeutics is actively participating in a significant healthcare conference.
  • The company focuses on developing biologics for neurodegenerative disorders.
  • Panel discussion highlights important diseases like ALS and Alzheimer's.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+10%
120-day peak, hindsight
Typical move
2%
average across 2 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
COYA 302
Phase 2 · Amyotrophic Lateral Sclerosis (ALS)

Full Press Release Details

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, today announced the company will be participating in a panel discussion at Chardan's 10th Annual Healthcare Conference taking place on October 20 in New York.Panel Details:Title: Targeting Neurodegenerative & Neuromuscular Disease: ALS, DMD, Alzheimer's &

Frequently Asked Questions

What is the focus of Coya Therapeutics?

Coya Therapeutics develops biologics to enhance T-cell function in neurodegenerative disorders.

When is the Chardan Healthcare Conference?

The Chardan's 10th Annual Healthcare Conference is on October 20.

What diseases will be discussed at the panel?

The panel will discuss ALS, DMD, and Alzheimer's diseases.

Where is the conference taking place?

The conference will be held in New York.

ShareAdd on Google
Tags: COYA Coya Therapeutics neurodegenerative disorders healthcare conference Chardan ALS
Last updated: Oct 13, 2026

Biotech snapshot

Cash runway
$43M liquidity · $2M/mo burn
~16 mo
Low dilution risk
Lead asset
COYA 302Phase 2
Amyotrophic Lateral Sclerosis (ALS) →

Catalyst track record

+10%
best trade around COYA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for COYA.

See every catalyst's timing & PoA →